Selexipag
- Generic Name
- Selexipag
- Brand Names
- Uptravi, Uptravi Titration Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C26H32N4O4S
- CAS Number
- 475086-01-2
- Unique Ingredient Identifier
- 5EXC0E384L
- Background
Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. Marketed by Actelion Pharmaceuticals und...
- Indication
Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.
- Associated Conditions
- Pulmonary arterial hypertension WHO functional class I
- Associated Therapies
- -
New data could help Merck expand use of cardiovascular drug
Merck's Winrevair, added to background therapy, helped severe lung hypertension patients stay alive and avoid invasive care longer. The ZENITH trial's interim data showed Winrevair outperformed placebo, potentially expanding its use and peak annual earnings to $5 billion. Winrevair treats pulmonary arterial hypertension, improving walking speed and delaying complications, with the ZENITH study focusing on severe cases.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath